U.S. Markets close in 4 hrs 16 mins

Smith & Nephew plc (SNN)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
35.93+0.27 (+0.76%)
As of 11:42AM EDT. Market open.
People also watch
WMGIOFIXSYKCNMDSTE
Full screen
Previous Close35.66
Open36.01
Bid36.00 x 3300
Ask36.01 x 300
Day's Range35.93 - 36.05
52 Week Range26.97 - 36.05
Volume212,202
Avg. Volume418,367
Market Cap15.46B
Beta0.50
PE Ratio (TTM)20.46
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.74 (2.10%)
Ex-Dividend Date2017-03-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube3 days ago

    ETFs with exposure to Smith & Nephew Plc : August 14, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Smith & Nephew Plc Here are 5 ETFs with the largest exposure to SNN-US. Comparing the performance and risk of Smith & Nephew Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • Smith & Nephew Plc :SNN-US: Earnings Analysis: For the six months ended June 30, 2017 : July 31, 2017
    Capital Cube17 days ago

    Smith & Nephew Plc :SNN-US: Earnings Analysis: For the six months ended June 30, 2017 : July 31, 2017

    Categories: Yahoo FinanceGet free summary analysis Smith & Nephew Plc reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of Smith & Nephew Plc – Zimmer Biomet Holdings, Inc., Johnson & Johnson, Edwards Lifesciences Corporation, Boston Scientific Corporation, Stryker Corporation, C. R. Bard, Inc., Exactech, Inc. and ... Read more (Read more...)

  • Reuterslast month

    Robot wars: knee surgery marks new battleground for companies

    The world's top medical technology companies are turning to robots to help with complex knee surgery, promising quicker procedures and better results in operations that often leave patients dissatisfied. Demand for artificial replacement joints is growing fast, as baby boomers' knees and hips wear out, but for the past 15 years rival firms have failed to deliver a technological advance to gain them significant market share.